Affinage

FXYD3

FXYD domain-containing ion transport regulator 3 · UniProt Q14802

Length
87 aa
Mass
9.3 kDa
Annotated
2026-06-09
37 papers in source corpus 17 papers cited in narrative 17 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FXYD3 (Mat-8) is a small single-pass transmembrane protein that functions primarily as a tissue-specific auxiliary subunit of P-type ATPases, tuning ion transport in epithelial cells (PMID:15743908, PMID:17077088, PMID:35993520). It associates physically and selectively with the Na,K-ATPase α subunit — an interaction requiring Gly41 in its transmembrane domain for both complex formation and plasma membrane targeting — and decreases the apparent Na+ and K+ affinities of the pump while modulating its turnover (PMID:15743908, PMID:17077088, PMID:17409496, PMID:19109419). Two human splice isoforms (a short type I form and a long form with a 26-residue post-transmembrane insertion) exert distinct effects on pump ion affinities and both induce hyperpolarization-activated currents (PMID:7836447, PMID:17077088). As a Na,K-ATPase regulator FXYD3 supports vectorial Na+ and liquid absorption at the basolateral membrane of airway epithelia (PMID:35993520), is required for enterocyte differentiation and epithelial barrier integrity (PMID:19109419), and protects the pump from oxidative inhibition by promoting reversal of β1 subunit glutathionylation (PMID:26740212). Beyond the Na,K-ATPase, FXYD3 interacts with the ER Ca2+-ATPase SERCA2 in intestinal goblet cells to enhance Ca2+ uptake, supporting mucin glycosylation and the mucus barrier (PMID:41187059). FXYD3 additionally participates in signaling complexes: it competitively binds TRAF3 to promote IL-17R–ACT1 assembly and NF-κB/MAPK activation in keratinocytes (PMID:36693922), and forms a Src–ERα complex driving nongenomic estrogen signaling and tamoxifen resistance in breast cancer (PMID:30206184). Its expression is tightly controlled by TGF-β/Smad3/ZEB1 repression (PMID:21372379), CpG promoter methylation downstream of gluco-incretin signaling (PMID:25058609), and induction by ERα, IL-17A, and microbial short-chain fatty acids (PMID:36693922, PMID:41187059, PMID:26090296).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1995 High

    Established FXYD3 as an electrically active membrane protein, raising the first question of how a phospholemman-homologous protein influences transmembrane ion flux.

    Evidence Xenopus oocyte expression with electrophysiology and RNA blot

    PMID:7836447

    Open questions at the time
    • Whether FXYD3 is a bona fide Cl- channel or a regulator of an endogenous current was not resolved
    • No direct binding partner identified at this stage
  2. 2005 High

    Reframed FXYD3 from a putative channel to a regulatory subunit of the Na,K-ATPase, showing it modifies pump ion affinities and β-subunit glycosylation.

    Evidence Xenopus oocyte co-expression, electrophysiology, in situ tissue analysis, biochemical assays

    PMID:15743908

    Open questions at the time
    • Topology (single vs double transmembrane) left ambiguous
    • Physiological consequence of pump regulation in native tissue not tested
  3. 2006 High

    Defined two human splice isoforms with distinct topologies and showed both bind selectively to Na,K-ATPase but exert divergent effects on Na+/K+ affinity, explaining isoform-specific pump tuning.

    Evidence Co-IP, Xenopus oocyte co-expression, electrophysiology, CaCo-2 differentiation model

    PMID:17077088

    Open questions at the time
    • Functional significance of the long-isoform-specific affinity changes in vivo unknown
    • Selectivity for Na,K-ATPase over H,K-/Ca-ATPase mechanism not structurally defined
  4. 2005 Medium

    Addressed where FXYD3 resides, finding intracellular ER/nuclear-envelope localization in CHO cells, hinting that surface targeting is context-dependent.

    Evidence DsRed tagging, density-gradient fractionation, organelle marker co-localization in CHO-K1

    PMID:16132847

    Open questions at the time
    • Single cell type tested
    • Did not establish what controls ER retention versus plasma membrane delivery
  5. 2007 Medium

    Identified Gly41 in the transmembrane domain as essential for both Na,K-ATPase association and plasma membrane targeting, mechanistically coupling complex assembly to trafficking.

    Evidence Reciprocal Co-IP, site-directed mutagenesis, fluorescent tagging in colorectal cancer and CHO cells

    PMID:17409496

    Open questions at the time
    • Single lab, two orthogonal methods
    • Why CHO cells retain FXYD3 intracellularly while cancer cells display it at the surface unresolved
  6. 2008 High

    Showed FXYD3 is required for epithelial differentiation and barrier formation, linking its pump-regulatory role to a cellular phenotype.

    Evidence siRNA silencing, transepithelial resistance, differentiation markers, Na,K-ATPase activity assays in Caco-2

    PMID:19109419

    Open questions at the time
    • Causal chain from pump regulation to apoptosis/differentiation not dissected
    • Single cell model
  7. 2009 Medium

    Connected FXYD3 to cytoskeletal organization, showing wild-type but not a point-mutant restores cortical actin, implying a sequence-dependent structural role.

    Evidence Forced expression of WT vs mutant FXYD3 in lung cancer cells, actin imaging

    PMID:19893046

    Open questions at the time
    • Mechanism linking FXYD3 to actin (direct vs pump-mediated) unknown
    • Single readout, single lab
  8. 2010 Medium

    Revealed that a bacterial effector (ExoS) hijacks the FXYD3 transmembrane domain, exploiting its Na,K-ATPase/barrier-regulating function for pathogen translocation.

    Evidence Bacterial two-hybrid screen, pulldown, colocalization

    PMID:20805335

    Open questions at the time
    • Mechanistic validation in mammalian cells limited
    • Functional consequence on barrier inferred rather than directly demonstrated
  9. 2011 Medium

    Mapped upstream transcriptional control, showing TGF-β represses FXYD3 via Smad3 and the repressor ZEB1, while decoupling FXYD3 from EMT.

    Evidence siRNA, TβRI/Smad3 inhibitors, ZEB1 knockdown, RT-PCR in MCF-10A

    PMID:21372379

    Open questions at the time
    • Direct ZEB1 binding to FXYD3 promoter not shown
    • Single cell line
  10. 2014 Medium

    Established epigenetic regulation of FXYD3 and a function in insulin secretion, placing FXYD3 downstream of Ca2+ influx in beta-cells and under CpG-methylation control.

    Evidence Beta-cell overexpression, insulin secretion assay, promoter methylation, H3K4me3 ChIP, reporter assay

    PMID:25058609

    Open questions at the time
    • Molecular step at which FXYD3 inhibits secretion downstream of Ca2+ not defined
    • Single lab
  11. 2015 Medium

    Showed estrogen and tamoxifen induce FXYD3 through ERα via two routes (one ZEB1-dependent), linking hormone signaling to FXYD3 expression.

    Evidence Flow cytometry, ZEB1 siRNA, ERα-positive vs -negative cell comparison

    PMID:26090296

    Open questions at the time
    • Direct vs indirect ERα transcriptional control not resolved
    • Mechanism distinguishing estrogen and tamoxifen routes incomplete
  12. 2016 Medium

    Defined a protective role against oxidative pump inhibition, showing FXYD3 facilitates reversal of β1 subunit glutathionylation and modulates chemo/radiotherapy sensitivity.

    Evidence siRNA, Na,K-ATPase activity and glutathionylation assays, caspase 3/7 and viability assays in MCF-7

    PMID:26740212

    Open questions at the time
    • Biochemical mechanism of how FXYD3 promotes deglutathionylation unknown
    • Cell-line-dependent effect (MCF-7 vs MDA-MB-468) unexplained
  13. 2018 Medium

    Extended FXYD3 beyond ion transport into nongenomic estrogen signaling, identifying an FXYD3–Src–ERα complex and a SOX9 feedback loop driving tamoxifen resistance.

    Evidence Co-IP, SOX9 promoter binding, nuclear localization imaging, siRNA/overexpression in breast cancer stem cells

    PMID:30206184

    Open questions at the time
    • Direct vs scaffolded interactions within the complex not distinguished
    • How a membrane protein supports SOX9 nuclear localization unresolved
  14. 2022 High

    Confirmed FXYD3 as a functional Na,K-ATPase γ subunit in airway epithelia, mechanistically tying it to Na+ and liquid absorption physiology.

    Evidence scRNA-seq, IHC, siRNA, Ussing chamber short-circuit current, liquid absorption assays

    PMID:35993520

    Open questions at the time
    • Contribution relative to other FXYD subunits not quantified
    • Role in airway disease not tested
  15. 2023 High

    Uncovered an immune-signaling function: FXYD3 competitively displaces TRAF3 to promote IL-17R–ACT1 assembly and NF-κB/MAPK activation, validated by KO rescue of psoriasis-like disease.

    Evidence Co-IP, conditional keratinocyte knockout, IMQ psoriasis model, NF-κB/MAPK assays

    PMID:36693922

    Open questions at the time
    • Whether the same protein pool serves pump and IL-17 functions unknown
    • Structural basis of TRAF3 competition undefined
  16. 2025 High

    Identified SERCA2 as a second P-type ATPase partner, showing FXYD3 enhances ER Ca2+ uptake to support goblet-cell mucin glycosylation and the mucus barrier.

    Evidence Co-IP, intestinal-epithelial conditional KO, SERCA2 activity and ER Ca2+ assays, mucin glycosylation analysis, germ-free/colonization models

    PMID:41187059

    Open questions at the time
    • Structural determinants of SERCA2 vs Na,K-ATPase selectivity not defined
    • Whether SERCA2 regulation generalizes beyond goblet cells unknown
  17. 2025 Medium

    Mapped a domain-specific interaction with IRF7 linking FXYD3 to a cGAS/STING–JAK2/STAT5 feedback loop in cholangiocarcinoma progression.

    Evidence Co-IP, domain mapping, single-cell/spatial transcriptomics, in vivo siRNA nano-delivery

    PMID:41164952

    Open questions at the time
    • Single lab, not independently replicated
    • How a transmembrane protein engages the cytoplasmic IRF7 axis mechanistically unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single small transmembrane protein partitions among its multiple functional pools — P-type ATPase regulation (Na,K-ATPase and SERCA2) versus scaffolding of signaling complexes (TRAF3, Src/ERα, IRF7) — and what structural features dictate partner selectivity and subcellular targeting.
  • No structural model of FXYD3 in complex with any partner
  • Determinants of plasma membrane vs ER localization not defined
  • Whether signaling functions require or are independent of ion-pump regulation untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0060090 molecular adaptor activity 3
Localization
GO:0005635 nuclear envelope 2 GO:0005783 endoplasmic reticulum 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-382551 Transport of small molecules 3 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 1
Partners
ATP1A1ESR1IRF7SERCA2SOX9SRCTRAF3
Complex memberships
FXYD3-Src-ERalpha complexIL-17R-ACT1 complexNa,K-ATPase

Evidence

Reading pass · 17 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 FXYD3 (Mat-8) expression in Xenopus oocytes induces hyperpolarization-activated chloride currents, indicating it functions as a Cl- channel or Cl- channel regulator. The protein contains extracellular and transmembrane domains homologous to phospholemman but a distinct cytoplasmic domain lacking cAMP-dependent PKA and PKC consensus phosphorylation sites. Xenopus oocyte expression system, electrophysiology, RNA blot analysis The Journal of biological chemistry High 7836447
2005 FXYD3 (Mat-8) associates with Na,K-ATPase and modifies its transport properties, decreasing both the apparent affinity for Na+ and K+. Mouse FXYD3 may adopt a double-transmembrane topology due to a non-cleavable signal peptide. In Xenopus oocytes, FXYD3 can associate with both Na,K-ATPase and H,K-ATPase, but in stomach tissue it associates only with Na,K-ATPase because its expression is restricted to mucous cells lacking H,K-ATPase. FXYD3 also modulates glycosylation processing of the beta subunit of X,K-ATPase in a signal-peptide-dependent manner. Xenopus oocyte co-expression, electrophysiology, in situ analysis, biochemical assays Molecular biology of the cell High 15743908
2006 Two human FXYD3 splice variants exist: short FXYD3 (with a cleavable signal peptide and type I topology) and long FXYD3 (with a 26-amino acid insertion after the transmembrane domain), differentially expressed during CaCo-2 cell differentiation. Both isoforms co-immunoprecipitate with Na,K-ATPase but associate stably only with Na,K-ATPase isozymes, not with H,K-ATPase or Ca-ATPase, in Xenopus oocytes. Short human FXYD3 decreases apparent K+ and Na+ affinity of Na,K-ATPase over a large range of membrane potentials, whereas long FXYD3 decreases K+ affinity only at slightly negative/positive potentials and increases apparent Na+ affinity. Both isoforms induce hyperpolarization-activated currents. Co-immunoprecipitation, Xenopus oocyte co-expression, electrophysiology, Western blot, CaCo-2 differentiation model The Journal of biological chemistry High 17077088
2007 Mat-8 (FXYD3) tagged with Myc localizes to the plasma membrane in colorectal cancer cells and co-immunoprecipitates with the Na+/K+-ATPase alpha subunit. A Gly41→Arg mutation in the transmembrane domain abolishes association with the Na+/K+-ATPase alpha subunit and prevents plasma membrane localization, identifying Gly41 as essential for this interaction and surface targeting. Cys44→Ala or Cys49→Ala substitutions did not affect these properties. In CHO-K1 cells, Mat-8 localizes predominantly to intracellular membranes (ER/nuclear envelope). Reciprocal co-immunoprecipitation, site-directed mutagenesis, fluorescent protein tagging, subcellular localization in colorectal cancer and CHO cells Biological & pharmaceutical bulletin Medium 17409496
2005 Mat-8 (FXYD3) tagged with DsRed fluorescent protein localizes to intracellular membranes in CHO-K1 cells, specifically distributed in a distinct ER region and nuclear envelope, with partial overlap with ER markers; no colocalization with lysosomes, endosomes, or Golgi bodies was detected. Stable fluorescent protein tagging, subcellular fractionation by density gradient centrifugation, co-localization with organelle markers Biotechnology letters Medium 16132847
2008 FXYD3 silencing in Caco-2 cells promotes apoptosis and prevents cell differentiation (reduced alkaline phosphatase, villin, decreased transepithelial resistance) without affecting proliferation. FXYD3 deficiency increases the apparent Na+ and K+ affinities of Na,K-ATPase (reflecting loss of FXYD3-mediated pump regulation) and decreases maximal Na,K-ATPase activity via reduced turnover number, correlating with a shift in Na,K-ATPase isozyme expression characteristic of cancer cells. siRNA silencing, transepithelial resistance measurement, alkaline phosphatase/villin expression, Na,K-ATPase activity assays in Caco-2 cells Molecular biology of the cell High 19109419
2009 Forced expression of wild-type FXYD3, but not a somatic point mutant (D19H/g55c), restores well-demarcated cortical actin distribution in lung cancer cells that had lost FXYD3 expression, indicating FXYD3 plays a role in maintenance of cytoskeletal integrity through a mechanism dependent on its intact sequence. Forced expression of wild-type vs. mutant FXYD3 in lung cancer cells, actin cytoskeleton imaging The American journal of pathology Medium 19893046
2010 Pseudomonas aeruginosa type III effector ExoS directly binds FXYD3 via its transmembrane domain (the same domain that interacts with Na,K-ATPase), as shown by bacterial two-hybrid screen and pulldown assay. FXYD3 colocalizes with and regulates Na,K-ATPase, which controls tight junction structure and barrier function; ExoS binding to FXYD3 is proposed to facilitate bacterial translocation through the intestinal epithelial barrier. Bacterial two-hybrid screen, pulldown assay, colocalization studies Infection and immunity Medium 20805335
2011 TGF-β signaling represses FXYD3 mRNA expression in MCF-10A human mammary epithelial cells via a Smad3-dependent (but not Smad2-dependent) pathway, acting through the downstream transcriptional repressor ZEB1/δEF1. TβRI inhibitor or Smad3 inhibitor abolishes TGF-β-induced FXYD3 repression. FXYD3 knockdown does not change E-cadherin or N-cadherin expression, indicating FXYD3 is not directly required for EMT. siRNA knockdown, pharmacological inhibitors (TβRI inhibitor, Smad3 inhibitor), RT-PCR, immunofluorescence in MCF-10A cells Biological & pharmaceutical bulletin Medium 21372379
2014 In pancreatic beta-cells, FXYD3 overexpression reduces glucose-induced insulin secretion by acting downstream of plasma membrane depolarization and Ca2+ influx. FXYD3 expression is controlled by methylation of CpGs in its proximal promoter region, with increased methylation reducing transcription (evidenced by lower H3K4me3 at the transcription start site). Gluco-incretin signaling establishes this epigenetic silencing perinatally. Beta-cell overexpression, insulin secretion assay, promoter methylation analysis, ChIP for H3K4me3, transcription reporter assay PloS one Medium 25058609
2016 FXYD3 overexpression in MCF-7 breast cancer cells protects Na+/K+-ATPase from oxidative inhibition by facilitating reversal of glutathionylation of the β1 Na+/K+-ATPase subunit. ~50% siRNA-mediated reduction of FXYD3 increases β1 subunit glutathionylation and reduces Na+/K+-ATPase activity by ~50%. Suppression of FXYD3 amplifies doxorubicin- and γ-radiation-induced Na+/K+-ATPase inhibition, cell death, and apoptosis in MCF-7 but not in MDA-MB-468 cells. siRNA knockdown, Na+/K+-ATPase activity assay (colorimetric), glutathionylation measurement, caspase 3/7 apoptosis assay, cell viability assay Breast cancer research and treatment Medium 26740212
2018 FXYD3 interacts with Src and ERα to form an activated complex that triggers nongenomic estrogen signaling in ER+ breast cancer stem cells. SOX9 transcription factor directly promotes FXYD3 expression, and FXYD3 is required for SOX9 nuclear localization, forming a positive regulatory feedback loop. FXYD3 amplification mediates tamoxifen resistance. Co-immunoprecipitation (FXYD3-Src-ERα complex), SOX9 promoter binding assays, nuclear localization imaging, siRNA/overexpression functional assays Molecular cancer research : MCR Medium 30206184
2022 FXYD3 localizes to the basolateral membrane of all airway epithelial cell types and functions as a γ subunit of the Na/K-ATPase to facilitate Na+ and liquid absorption. siRNA-mediated reduction of FXYD3 decreases ouabain-sensitive short-circuit current (after apical membrane permeabilization with nystatin) and reduces amiloride-sensitive short-circuit current and liquid absorption across intact airway epithelia. Single-cell RNA sequencing, immunohistochemistry, siRNA knockdown, Ussing chamber short-circuit current measurements, liquid absorption assay American journal of physiology. Cell physiology High 35993520
2023 FXYD3 promotes IL-17A signaling in keratinocytes by competitively binding TRAF3, thereby promoting formation of the IL-17R-ACT1 complex (by displacing TRAF3 from IL-17R), which activates NF-κB and MAPK signaling pathways and drives proinflammatory cytokine expression. FXYD3 deletion in keratinocytes attenuates psoriasis-like phenotype in an IMQ-induced mouse model. IL-17A drives FXYD3 expression in keratinocytes, forming a positive regulatory loop. Co-immunoprecipitation (FXYD3-TRAF3-IL-17R-ACT1 complex), FXYD3 conditional knockout mouse model, IMQ-induced psoriasis model, NF-κB/MAPK signaling assays Cellular & molecular immunology High 36693922
2025 FXYD3 in intestinal goblet cells interacts with the ER Ca2+-ATPase SERCA2 to enhance its pump activity. FXYD3 deficiency causes ER Ca2+ homeostasis defects and impaired mucin glycosylation, leading to a damaged mucus barrier, intestinal dysbiosis, and increased susceptibility to colitis. Gut microbiota metabolites propionate and butyrate promote FXYD3 expression. Co-immunoprecipitation (FXYD3-SERCA2), FXYD3 conditional knockout (intestinal epithelial), SERCA2 activity assay, ER Ca2+ measurement, mucin glycosylation analysis, germ-free/colonization models Cell reports High 41187059
2025 FXYD3 directly interacts with IRF7 via its 60–87 amino acid domain, initiating a positive feedback loop through the cGAS/STING pathway amplified by type I interferon, resulting in sustained JAK2/STAT5 signaling activation that drives malignant progression of intrahepatic cholangiocarcinoma. Co-immunoprecipitation, single-cell sequencing, spatial transcriptomics, domain mapping, in vitro and in vivo functional assays, nano-delivery siRNA system Advanced science Medium 41164952
2015 Estrogen and tamoxifen upregulate FXYD3 expression in ERα-positive MCF-7 cells via ERα, but not in ERα-negative MDA-MB-231 cells, establishing ERα as required for this response. ERα associates with ZEB1 in MCF-7 cells, and siRNA knockdown of ZEB1 disrupts estrogen- (but not tamoxifen-) induced FXYD3 upregulation, indicating two distinct mechanisms both involving ERα, one requiring ZEB1. Flow cytometry (fluorochrome-tagged antibody), siRNA knockdown of ZEB1, comparison of ERα-positive vs ERα-negative cell lines SpringerPlus Medium 26090296

Source papers

Stage 0 corpus · 37 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1995 Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes. The Journal of biological chemistry 138 7836447
2004 Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. International journal of oncology 82 14654946
2010 Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator, FXYD3. Infection and immunity 70 20805335
2006 FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. International journal of cancer 63 16003754
2005 FXYD3 (Mat-8), a new regulator of Na,K-ATPase. Molecular biology of the cell 61 15743908
2020 Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis. Journal of cellular and molecular medicine 46 33350586
2018 SOX9/FXYD3/Src Axis Is Critical for ER+ Breast Cancer Stem Cell Function. Molecular cancer research : MCR 46 30206184
2009 Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. The American journal of pathology 36 19893046
2023 FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes. Cellular & molecular immunology 33 36693922
2021 KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation. Journal of cellular and molecular medicine 29 33621431
2009 Expression of FXYD3 protein in relation to biological and clinicopathological variables in colorectal cancers. Chemotherapy 26 19955746
2006 Structural and functional properties of two human FXYD3 (Mat-8) isoforms. The Journal of biological chemistry 26 17077088
2009 FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biological & pharmaceutical bulletin 23 19571376
2007 Interaction of Mat-8 (FXYD-3) with Na+/K+-ATPase in colorectal cancer cells. Biological & pharmaceutical bulletin 23 17409496
2011 Down-regulation of FXYD3 is induced by transforming growth factor-β signaling via ZEB1/δEF1 in human mammary epithelial cells. Biological & pharmaceutical bulletin 22 21372379
2008 A link between FXYD3 (Mat-8)-mediated Na,K-ATPase regulation and differentiation of Caco-2 intestinal epithelial cells. Molecular biology of the cell 21 19109419
2011 FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomarker insights 20 21499437
2023 TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. PloS one 17 37535601
2023 FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters. The Journal of clinical investigation 17 37966117
2020 LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression. Bioscience reports 17 32432654
2010 Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Disease markers 17 20364041
2014 Expression and clinical significance of FXYD3 in endometrial cancer. Oncology letters 16 25013464
2016 Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na(+)/K(+)-ATPase and cell survival. Breast cancer research and treatment 14 26740212
2013 Overexpression of FXYD-3 is involved in the tumorigenesis and development of esophageal squamous cell carcinoma. Disease markers 13 24167366
2009 FXYD3 expression in gliomas and its clinicopathological significance. Oncology research 13 20112499
2020 Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis. ACS sensors 12 32162907
2014 Gluco-incretins regulate beta-cell glucose competence by epigenetic silencing of Fxyd3 expression. PloS one 12 25058609
2015 External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. Actas urologicas espanolas 10 25920992
2005 Stable expression and visualization of Mat-8 (FXYD-3) tagged with a fluorescent protein in Chinese hamster ovary (CHO)-K1 cells. Biotechnology letters 10 16132847
2003 Fxyd3 and Lgi4 expression in the adult mouse: a case of endogenous antisense expression. Mammalian genome : official journal of the International Mammalian Genome Society 10 14694902
2015 Estrogen and tamoxifen up-regulate FXYD3 on breast cancer cells: assessing the differential roles of ER α and ZEB1. SpringerPlus 9 26090296
2016 FXYD-3 expression in relation to local recurrence of rectal cancer. Radiation oncology journal 6 27104167
2025 Goblet cell-expressed microprotein FXYD3 determines gut homeostasis by maintaining mucus barrier integrity. Cell reports 4 41187059
2024 Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer. American journal of cancer research 4 39417182
2022 FXYD3 facilitates Na+ and liquid absorption across human airway epithelia by increasing the transport capacity of the Na/K ATPase. American journal of physiology. Cell physiology 4 35993520
2025 FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2 41164952
2025 FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Cancer medicine 1 39783776

Missed literature

Know a paper Affinage missed for FXYD3? Flag it for the maintainers and the community.

No submissions yet.